Focus: Recursion Pharmaceuticals is a public biotech company pioneering automated, software-based drug discovery platforms to accelerate identification and development of novel therapeutics. The company operates at the intersection of computational biology and traditional pharma, with early-stage clinical programs primarily in neurology and oncology.
Profile data last refreshed 1h ago · AI intelligence enriched 1mo ago
Stable — net -4 jobs in 30d
16 added, 20 removed. Backfill posture.
Recursion is a high-risk, high-innovation opportunity suited for technologists and early-stage drug development professionals betting on AI-enabled discovery; traditional pharma operators should assess tolerance for extended pre-revenue phase and platform dependency.
Help build intelligence for Recursion Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Recursion Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline and Recent Financial Results - Quiver Quantitative
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline and Recent Financial Results Quiver Quantitative
8-K Filing: Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070) — FORM OF CONTINGENT VALUE RIGHTS AGREEMENT
FORM OF CONTINGENT VALUE RIGHTS AGREEMENT
Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes Yahoo Finance
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? - The Motley Fool
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? The Motley Fool
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? - The Motley Fool
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? The Motley Fool
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo